Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP
Executive Summary
MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class
You may also be interested in...
Specialty Pharmacies Adopting PBM Formulary Management Practices
Pharmacy benefit manager formulary management practices are increasingly being used by specialty pharmacies, attendees said at the Pharmaceutical Care Management Association specialty pharmacy annual meeting in Palm Springs, Calif. Oct. 25
Specialty Pharmacies Adopting PBM Formulary Management Practices
Pharmacy benefit manager formulary management practices are increasingly being used by specialty pharmacies, attendees said at the Pharmaceutical Care Management Association specialty pharmacy annual meeting in Palm Springs, Calif. Oct. 25
MGI Saforis NDA To Be Based On Single Phase III Trial; Filing Planned For Q3
MGI Pharma expects to file an NDA for Saforis (l-glutamine oral suspension) for the treatment of oral mucositis based on the results of one Phase III trial and supportive earlier-phase trials